Company / R&D per Share
Kiniksa Pharmaceuticals International, plc R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.35
FY2025
5-year range
$1.06 / $2.50
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#131 of 208
Health Care
What the data says
At $1.35, Kiniksa Pharmaceuticals International, plc's r&d per share ranks #131 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 9 years, ranging from $1.06 in FY2022 to $31.14 in FY2017.
Based on SEC 10-K filings.
1.35 in FY2025 with a 5-year CAGR of -5.8%.
Improved from $1.11 to $1.35 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +8.3%
- 5-Year CAGR
- -5.8%
- 10-Year CAGR
- -
Sector benchmark
#131 of 208 in Health CareTop 63% of 208This company $1.35 Sector average $12.19
▼
-89.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 15.0% year-over-year.
- Ranks #131 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.35 | -15.0% |
| FY2024 | $1.59 | +42.8% |
| FY2023 | $1.11 | +4.8% |
| FY2022 | $1.06 | -57.6% |
| FY2021 | $2.50 | +37.9% |
| FY2020 | $1.81 | -27.5% |
| FY2019 | $2.50 | -14.8% |
| FY2018 | $2.93 | -90.6% |
| FY2017 | $31.14 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026